Cylindrical Microparticles Composed of Mesoporous Silica Nanoparticles for the Targeted Delivery of a Small Molecule and a Macromolecular Drug to the Lungs: Exemplified with Curcumin and siRNA by Fischer, Thorben et al.
pharmaceutics
Article
Cylindrical Microparticles Composed of Mesoporous Silica
Nanoparticles for the Targeted Delivery of a Small Molecule
and a Macromolecular Drug to the Lungs: Exemplified with
Curcumin and siRNA
Thorben Fischer 1, Inga Winter 1, Robert Drumm 2 and Marc Schneider 1,*


Citation: Fischer, T.; Winter, I.;
Drumm, R.; Schneider, M. Cylindrical
Microparticles Composed of
Mesoporous Silica Nanoparticles for
the Targeted Delivery of a Small
Molecule and a Macromolecular
Drug to the Lungs: Exemplified with
Curcumin and siRNA. Pharmaceutics




Received: 14 May 2021
Accepted: 2 June 2021
Published: 7 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University,
Campus C4 1, 66123 Saarbruecken, Germany; thorben.fischer@uni-saarland.de (T.F.);
s9wiing@stud.uni-saarland.de (I.W.)
2 INM-Leibniz Institute for New Materials, Campus D2 2, 66123 Saarbruecken, Germany;
robert.drumm@leibniz-inm.de
* Correspondence: Marc.Schneider@uni-saarland.de; Tel.: +49-681-302-2438
Abstract: The transport of macromolecular drugs such as oligonucleotides into the lungs has become
increasingly relevant in recent years due to their high potency. However, the chemical structure
of this group of drugs poses a hurdle to their delivery, caused by the negative charge, membrane
impermeability and instability. For example, siRNA to reduce tumour necrosis factor alpha (TNF-α)
secretion to reduce inflammatory signals has been successfully delivered by inhalation. In order
to increase the effect of the treatment, a co-transport of another anti-inflammatory ingredient was
applied. Combining curcumin-loaded mesoporous silica nanoparticles in nanostructured cylindrical
microparticles stabilized by the layer-by-layer technique using polyanionic siRNA against TNF-α
was used for demonstration. This system showed aerodynamic properties suited for lung deposition
(mass median aerodynamic diameter of 2.85 ± 0.44 µm). Furthermore, these inhalable carriers
showed no acute in vitro toxicity tested in both alveolar epithelial cells and macrophages up to
48 h incubation. Ultimately, TNF-α release was significantly reduced by the particles, showing an
improved activity co-delivering both drugs using such a drug-delivery system for specific inhibition
of TNF-α in the lungs.
Keywords: nanotechnology; pulmonary delivery; TNFalpha inhibition; RNA release; inhalation
therapy; aspheric drug delivery systems; curcumin delivery; synergistic effect
1. Introduction
According to the World Health Organization (WHO), chronic respiratory diseases
are among the most widespread diseases worldwide with a high mortality rate, which
is expected to increase further in the future [1]. With several million cases, cystic fibro-
sis, idiopathic pulmonary fibrosis, tuberculosis, chronic obstructive pulmonary disease
(COPD) and asthma represent the most common diseases for this clinical pattern [2], lead-
ing to a permanent inflammation [3–6] and thus affect the lung function over time [6,7].
This proinflammatory status is caused by dysregulation of gene expressions, resulting
in an imbalance of produced transcription factors [8], which translates into increased re-
lease of proinflammatory mediators such as cytokines [9]. The cell populations such as
macrophages and immunologically active epithelial cells, which are mainly responsible for
the production and release of these messenger substances, are located in the alveolar region
of the lungs [10]. In a chronic inflammatory state, the continuous secretion of cytokines
and proinflammatory mediators may lead to additional deterioration of the lung tissue.
The interruption of the hyperinflammatory, ongoing release of cytokines will support
treatment [11].
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To reach the deep lungs, several inhalation systems have been developed to generate
the highest possible efficiency. Most commonly used for pulmonary delivery are dry
powder inhalers (DPIs), metered dose inhalers (MDIs), soft mist inhalers (SMIs) and
nebulizers [12]. Having a closer look at DPIs, usually powder mixtures of the micronized
drug particles are mixed with inert substances such as lactose, mannitol, trehalose, etc.
in order to deliver the drug as efficiently as possible to its target [13]. Spray-drying is
often applied, providing suitable particles for inhalation, although many commercial
formulations are reported to have a lung deposition as low as 14% [14].
A relatively new drug carrier for lung application is mesoporous silica particles.
Although a novel approach, they are already commercially offered as a pulmonary transport
system due to their various positive characteristics [15]. Especially, mesoporous silica
nanoparticles (mSNPs) are more biocompatible due to their structure, which results in
faster degradation and thus a lower toxic potential in comparison to amorphous silica
nanoparticles [16]. In addition, the mSNPs can be loaded in high quantities [17] with labile
molecules, such as curcumin, as the pores create a protective environment [18]. This is also
one of the reasons why such particulates were already intensively used as a drug delivery
system for various application routes for diverse targets [19–21].
The filled pores have only a small area where the outer medium comes into contact
with the drug, leading to a slower release [22]. In addition, to further modify the release
and better protect labile drugs in the pores, the surface of the mSNPs can be coated
with polymers. Here, the strong negative surface charge of the silica particles can be
exploited [18]. An established method for this is the layer-by-layer technique [23]. This
allows not only the surface to be loaded with drugs, but also polymers to be used as
stabilizers for the formation of larger particle constructs [24,25]. This property can be used
to manufacture drug delivery systems for pulmonary application, where an aerodynamic
diameter of 1–5 µm must be achieved to reach the deep lungs [26].
To generate a stronger cell response and inhibit the release of proinflammatory cy-
tokines, mSNPs can be loaded in the pores with multiple anti-inflammatory agents, such
as the natural compound curcumin, and also a negatively charged oligonucleotide, such
as a specific siRNA, on the surface to generate an improved effect [27]. However, since
these two drugs have low stability and critical pharmacokinetic properties [28–30], tar-
geted transport into immunologically active cells is of particular importance to prevent
disintegration and also reduce side effects [31]. The use of aspheric particles for pulmonary
delivery represents a possible mode of delivery for this purpose since the change in shape
affects the interaction with immunological cells such as macrophages [32]. Here, a cylin-
drical shape has been established, since a change in the length-width ratio, also called
aspect ratio, leads to a modified cell uptake into macrophages [33]. In addition, the specific
surface area of cylindrical microparticles is significantly larger than the surface area of their
spherical counterparts, which allows higher loading quantities. This drug delivery system
has already shown that loading with a specific siRNA sequence against TNF-α is possible
and a significant reduction in this cytokine release from macrophages could be achieved,
but also showed the need for improvement [24].
The idea was to provide a drug carrier system able to interact with alveolar macrophages
and allow an efficient reduction in TNF-α release. Delivery of sensible macromolecular
drugs in combination with a supportive conventional small molecule is a novel approach.
The formulation shall load and protect sensible drugs and deliver it via oral inhalation.
The exploitation of the advantages of mSNPs assembled to inhalable cylinders for siRNA
delivery is an approach not yet described. The aim was to develop a nanostructured
cylindrical drug carrier system composed of mSNPs to ensure the directed transport of
siRNA in macrophages. Supplemental curcumin as an additional anti-inflammatory agent
was used to achieve a synergistic effect and further reduce the release of cytokines. In
this work, we focused on the inhibition of tumour necrosis factor alpha (TNF-α) as one of
the most prominent and active cytokines in the inflammation cascade [34]. Such a system
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should allow enhancement of the effect combining the two drug types and may underline
the potential of such a carrier system for future applications.
2. Materials and Methods
2.1. Materials
Mesoporous silica nanoparticles with a pore size of 4 nm and a diameter of 200 nm
(748161-1G) as well as curcumin (C1386-50G), branched polyethyleneimine (bPEI) 25 kDa
(408727-100ML), L-leucine (L8000-25G) and 3-aminopropyltrimethoxy silane (APTS) (440140-
100ML) were purchased from Sigma Aldrich (Steinheim, Germany). Dextran sulphate 10 HS
(DB008) was purchased from TdB Labs (Uppsala, Sweden). Nuclepore® Track-Etched
Membranes with a pore size from 0.1 µm (WHA110605) and 3 µm (WHA110612) in di-
ameter were purchased from Whatman plc (Kent, UK). RPMI-1640 cell culture medium
(R8758-500ML), Hanks’ Balanced Salt solution (HBSS) (H9394-500ML), dimethyl sulphoxide
(DMSO) (472301-500ML), phorbol 12-myristate 13-acetate (PMA) (79346-5MG), lipopolysac-
charides from Escherichia coli (LPS) (L2880-10MG), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (M5655-100MG), foetal bovine serum (FCS) (F2442-
500ML) and ethidium bromide solution (E1510-10ML) were obtained from Sigma Aldrich
Life Science GmbH (Seelze, Germany). Nuclease-Free Water (AM9939), TNF alpha Human
ELISA Kit (KHC3011) and tetrahydrofuran (109-99-9) were obtained from Thermo Fisher
Scientific Inc. (Darmstadt, Germany). Silencer® Pre-designed siRNA (sequences: Sense (5′-
GGACGAACAUCCAACCUUCtt-3′) Antisense (5′-GAAGGUUGGAUGUUCGUCCtc-3′))
(AM16706) was purchased from Ambion Inc (Austin, TX, USA). Silencer™ Select Negative
Control No. 1 siRNA (Sequences: Sense (5′-UAACGACGCGACGACGUAAtt-3′) Antisense
(5′-UUACGUCGUCGCGUCGUUAtt-3′)) used as negative control for siRNA (scrambled
siRNA) (4390844) was purchased from Invitrogen™ (Carlsbad, CA, USA).
2.2. Rhodamine B Functionalization of mSNP for Visualization
In order to improve the detection and quantification of the colourless nanoparticles in
various experiments, a fluorescent dye was added. Therefore, 3-aminopropyltrimethoxy
silane (APTS) was covalently bound to the hydroxy groups on the surface of the silica
particles [35]. Beforehand, the primary amine group of APTS was bound with the carboxy
group of rhodamine B to form an amide. This compound was then applied to functionalize
the surface of the nanoparticles by covalently attaching the rhodamine B silane to the
surface via the methoxy silanes. For this, a 3% rhodamine B solution in chloroform was
prepared and mixed with APTS. This mixture was heated for 30 min to 60 ◦C under
stirring. The remaining chloroform was then evaporated, and the residue was dissolved
in ethanol and adjusted to pH 3.5 using 0.5 N hydrochloric acid. The resulting solution
was then allowed to react for 1 h while stirring. Subsequently, mSNPs were mixed in a
ratio of 1:10 with the prepared solution and incubated for 6 h while shaking in a thermal
mixer at 60 ◦C. The suspension was then washed twice with ethanol until no unreacted
fraction of rhodamine B was present [36]. This should result in fluorescent, violet-stained
nanoparticles with an excitation wavelength of 545 nm and an emission wavelength of
567 nm, allowing straightforward quantification.
2.3. BET Measurement to Evaluate Pore Volume and Loading with Curcumin
The measurement of the adsorption isotherm after Brunauer, Emmett and Teller (BET)
determines the monolayer concentration of an adsorbed gas on the sample surface. From
this value, the specific surface of the sample can be determined. The physical adsorption
observed is based on van der Waals interactions between the adsorbed gas molecules
and the adsorbing sample surface. Usually, nitrogen is used as adsorption gas in this
method, as far as the temperatures and the sample allow it. The specific surface area
determined in a BET measurement also includes the surface area of pores in porous
materials and is therefore in relation to the relative surface area. Gas adsorption thus
enables the determination of the size and volume distribution of micropores. In addition,
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comparative measurements can be used to directly check loading tests and to determine
the loading quantities. For sample preparation, the powder was first dried in vacuum at
an elevated temperature followed by the measurement at the boiling point of nitrogen.
After recording at least three data points, the BET value can be determined using the BET
adsorption isothermal equation (Equation (1)). The amount of adsorbed gas is correlated













p = partial vapor pressure of the adsorbed gas in equilibrium with the surface at 77.4 K
(boiling point of liquid nitrogen) (Pa);
p0 = saturation pressure of the adsorbed gas (Pa);
Va = volume of adsorbed gas under standard conditions (273.15 K and 1.013 × 105 Pa) (mL);
Vm = volume of the adsorbed gas, to enable monolayer formation on the sample surface
(mL);
C = dimensionless constant related to the adsorption enthalpy of the adsorbing gas on the
powder sample.
For sample preparation, 0.2951 g of mSNPs were added to a quartz cell and evacuated
for 10 h at 130 K (degassing) to remove physically adsorbed water and volatiles on the
surface of the particles followed by the adsorption cycle at 77.4 K. As reference, the
quartz cell without sample was degassed under the same conditions and subsequently
an adsorption cycle was performed. Nitrogen was used as adsorbate gas as it is inert and
interacts with most solids. The pressure difference between the sample and the standard
correlates with the amount of adsorbed nitrogen. From this, the surface area and the pore
volume can be determined.
2.4. mSNP Pore Loading with Curcumin
To load the pores of the mSNPs, 2 mg of curcumin was dissolved in 1 mL of acetonitrile
and subsequently 10 mg of nanoparticles were added to the solution. This suspension was
first homogenized in an ultrasonic bath and then heated for 1 h at 90 ◦C and 500 rpm to
evaporate the solvent. By reducing the volume of the solvent, the hydrophobic drug is
forced into the pores of the nanoparticles, due to the increasing curcumin concentration
by solvent evaporation. Only a small amount of the curcumin attaches to the hydrophilic
surface of the nanoparticles and was removed by washing with water for three times.
To confirm this hypothesis, this loading method was first performed with non-porous,
non-fluorescently labelled silica particles.
2.5. Determination of Colloidal Properties
Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK) was used to determine hydrody-
namic diameter via dynamic light scattering. Here, the polydispersity index (PDI) was also
determined describing the size distribution of the nanoparticles. The same device was used to
determine the zeta potential according to the principle of laser doppler micro electrophoresis.
For sample preparation, a stock solution of 1 mg/mL was diluted 1:20 with MiliQ® water
and measured three times, with each of the three measurements including 12 runs.
2.6. Preparation of Cylindrical Microparticles Composed of mSNPs
To produce the nanostructured cylindrical microparticles (microrods), the mSNPs
must first be assembled in a cylindrical shape. Therefore, a template-assisted approach was
used [25,38] to transfer the nanoparticles into a template membrane with a defined length
and width of 10 µm and 3 µm. This shaping membrane was placed into a filter holder
system, which was sealed with a silicon ring. A second membrane was added as a blocking
membrane underneath the template membrane. Thus, the mSNPs remained in the pores of
the template membrane, allowing only the water of the suspension to pass through the
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small pores (d = 0.05 µm) of the blocking membrane. A syringe containing 500 µL of a
1.5 mg/mL mSNP suspension was connected to the filter holder, continuously injecting
particles into the pores of the template membrane with a flowrate of 100 µL/min created by
a syringe pump (Legato 210; KD Scientific, Holliston, MA, USA). This process was repeated
three times to achieve uniform filling. Afterwards, the template membrane was washed
with a lint-free tissue to remove the particles on the top and bottom of the membrane.
Since the particles are only loosely assembled and not connected strongly to each other
in the pores, the layer-by-layer technique was used to increase the ionic interactions and
thus stabilize the microrods [39,40]. Polycationic substances branched polyethyleneimine
(bPEI) was used and dextran sulphate was applied due to its negative charge. These
substances were used because they offer relevant properties. Dextran sulphate is highly
branched and thus yields many anionic groups due to the high number of sulphate groups
per glycosyl unit (approximately 2.3) [41] and it is biocompatible [42]. bPEI was used
because this polymer has a strong buffering capacity, which is described to promote osmotic
swelling of the lysosome and thus destabilizes the membrane of the vesicle. Through this
so-called “’proton sponge effect” the diffusion of the active ingredients into the cytosol
shall be facilitated [43] allowing reaching the target in the cytosol [34]. In a first step,
the template membrane with the infiltrated mSNP was added to 2% bPEI solution for
12 min to allow the cationic polymer to adhere to the negatively charged surface of the
nanoparticles. After a subsequent washing step with water, the membrane was placed
in a 2% dextran sulphate solution for 12 min. After a second washing step, this cycle
of layering was repeated. A total of three double layers (PEI and dextran sulphate form
one double layer) of the polymers was necessary to generate a stable formulation. To
load the particles with siRNA, the dextran sulphate solution was replaced by an 0.05%
siRNA solution in the last layering step. To release the stabilized formulation from the
polycarbonate template membrane, it was dissolved in tetrahydrofuran (THF). The THF
insoluble microrods were then centrifuged at 6500× g for 7 min and the supernatant
containing dissolved polycarbonate was discarded. Washing with THF was performed five
times in total and after the last step the inorganic solvent was evaporated, resulting in a
dry powder. Since the oligonucleotide used is sensitive to nucleases, the entire production
process was performed under aseptic conditions.
2.7. Aerodynamic Characteristics Analysed by Next Generation Impactor
Since the developed formulation was intended for inhalation into the lungs, the
aerodynamic properties were determined. Therefore, a Next Generation Impactor (NGI)
(Copley Scientific, Nottingham, UK) with standardized settings was used [44]. An M1A
flowmeter (Copley Scientific, Nottingham, UK) was used to adjust a continuous airflow
of 60 L/min ensuring aerosolization of the microparticles [45,46]. These were coated with
L-leucine at the surface [47] before application to reduce hygroscopicity [48] and increase
surface roughness to improve flight characteristics [49,50]. Approximately 3 mg of the
coated formulation was then filled into a capsule, placed in a HandiHaler® (Boehringer In-
gelheim, Ingelheim, Germany) and punctured. An air flow of 60 L/min was then generated
for 4 s by a vacuum pump (Erweka, Langen, Germany) to aerosolize the formulation into
the NGI. The particle concentrations in each stage were then analysed using a microplate
spectrophotometer (TecanReader® infinite M200, Tecan, Männedorf; Switzerland) to de-
termine the Mass Median Aerodynamic Diameter (MMAD), Fine Particle Fraction (FPF)
and Geometric Standard Deviation (GSD). The calculation of these values was performed
analogous to Abdelrahim et al. [51] as already described in different publications [52,53].
2.8. Differentiation of Human Monocytes (THP-1) into Macrophage-Like Cells
To determine the interaction between the developed formulation and immunologically
active cells, the human monocytic cell line THP-1 was used. In a first step, this cell line
must be differentiated into M0 macrophage-like cells. Therefore, the cells were incubated
with a mixture of RPMI 1640 medium with an addition of 10% foetal calf serum (FCS)
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and 50 ng/mL phorbol 12-myristate 13-acetate (PMA) for three days in a humidified
atmosphere of 5% carbon dioxide at 37 ◦C. Afterwards, the cells were washed twice
with HBSS and supplemented with medium without PMA. The cells resulting from the
differentiation process represent a M0 macrophage-like cell line (dTHP-1) [54]. As the
method is well established, the successful differentiation was only monitored by light
microscopy evaluation of the form of the cells and the fact that they turn into adhesive cells
growing on the support.
2.9. Human Alveolar Basal Epithelial Cell Line A549
Since not only immunologically active cell types interact with the formulation during
pulmonary application of drug delivery systems, the A549 cell line was used as model for
pulmonary epithelial cells to analyse possible reactions [55]. To cultivate the cells, they
were incubated with RPMI 1640 medium with an addition of 10% FCS in a humidified
atmosphere of 5% carbon dioxide at 37 ◦C.
2.10. Determination of Cell Viability by MTT Assay
To get a first impression of how the cells interact with the developed formulation,
a cytotoxicity test was performed. For this study, the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid (MTT) assay was applied to colourimetrically determine the
metabolic activity of the cells after incubation with the drug delivery system [56]. For this,
the cell lines A549 and dTHP-1 described above were cultivated in 96-well plates with a
concentration of 2 × 104 cells per well. Subsequently, the cells were incubated for 4, 24
and 48 h with a particle concentration of 10, 50 and 100 µg/mL, respectively. To obtain
these concentrations, the formulation was redispersed and diluted in RPMI 1640 + 10%
FCS. After different periods of time, the supernatant was removed and replaced by MTT
reagent incubating for 4 h. In a final step, the supernatant was removed and replaced with
DMSO to dissolve the resulting formazan crystals. Cell viability was then determined by
measuring the absorbance at 550 nm after 20 min using microplate spectrophotometer.
Untreated cells grown in medium and Triton-X treated cells were used a negative and
positive control, respectively.
2.11. In Vitro Release of siRNA and Curcumin under Phagolysosomal Conditions
When incubating cells with particles, usually not 100% of the active ingredient is
released in time [57]. Therefore, it is unclear what amount is available for drug action.
Consequently, a release study in phagolysosomal simulant fluid (PSF) [58] was performed
to determine the amount of released drug in a phagolysosomal-like milieu for correlating
the results with the later performed Enzyme Linked Immunosorbent Assay (ELISA) for
cytokine determination. For the procedure, the formulation was placed in different micro
reaction tubes under sink conditions and incubated at 37 ◦C with gentle shaking for 1,
2, 3, 4, 6, 24 and 48 h. To analyse the released amount, the tubes were centrifuged at
24,000×g for 30 min. The resulting supernatant was then analysed using a microplate
spectrophotometer. To determine the curcumin content, the supernatant was mixed 1:1
with ethanol to facilitate dissolution of the compound and measured at λex = 430 nm and
λem = 535 nm. For quantification of the released oligonucleotides, the supernatant was
mixed with ethidium bromide followed by fluorescence measurement at λex = 526 nm and
λem = 605 nm [59]. Each value was determined as independent triplicate.
2.12. Quantification of TNF-α Release by Enzyme Linked Immunosorbent Assay (ELISA)
To detect the influence of the developed formulations on the cytokine release (TNF-α)
of the macrophage-like dTHP-1 cells after induced inflammation by lipopolysaccharide
(LPS), an ELISA was performed [60]. A total of 200,000 THP-1 cells were seeded per well in
a 24-well plate and differentiated with PMA to M0 macrophages as described in the section
above. Subsequently, the cells were incubated with 500 µL of the different microrod formu-
lations and a concentration of 40, 200 and 400 µg/mL for 2 days at 37 ◦C in a humidified
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atmosphere of 5% carbon dioxide. These concentrations represent the same concentrations
per cell as used in the cytotoxicity assay. After incubation, the supernatant was discarded
and replaced by 500 µL of 200 µg/mL LPS from Salmonella typhimurium for 6 h to induce
inflammation of the macrophages leading to an increased release of proinflammatory
cytokines such as TNF-α [61]. The resulting supernatants were then centrifuged at 200× g
for 10 min to remove cell residues and finally analysed by ELISA for the cytokines. As a
positive control (PC), dTHP-1 stimulated with LPS for 6 h without treatment were used.
Untreated cells served as a negative control (NC). Further controls included the plain
drugs curcumin and siRNA without a carrier system, as well as scrambled siRNA with and
without carrier were used to exclude possible unspecific reactions with oligonucleotides.
2.13. Scanning Electron Microscopy for Analysis of Rod Morphology
Morphology of the nanostructured microrods was determined by scanning electron
microscopy (SEM). For visualization, a Zeiss Evo HD 15 Electron Microscope (Carl Zeiss
AG, Jena, Germany) was used, equipped with a Lanthanum hexaboride (LaB6) cathode. To
prepare the samples for the measurement, the microrods were redispersed in water and a
few drops of the suspension were placed on a silica wafer and left to dry. These samples
were then sputtered with an approximately 10 nm thick gold layer using a Quorum Q150R
ES sputter coater (Quorum Technologies Ltd., East Grinstead, UK) to minimize surface
artifacts and allow high magnifications [62]. The images were taken at a voltage of 5 kV
and a magnification of 15 kX.
2.14. Confocal Laser Scanning Microscopy for Particle Visualization
In addition to SEM visualization, confocal laser scanning microscopy (CLSM) (LSM710,
Carl Zeiss AG, Jena, Germany) was used to characterize the morphology of the microrods.
Therefore, the formulation was redispersed in water and dropped onto a glass slide and
covered with a cover glass. To visualize the rhodamine B-labelled microrods, λex = 545 nm
and λem = 567 nm were used; for curcumin, λex = 440 nm and λem = 542 nm; and for
the siRNA stained with ethidium bromide, λex = 526 nm and λem = 605 nm. For the
measurement, a water corrected objective M27 was used with a magnification of 40× and a
numerical aperture of 1.2.
2.15. Statistical Evaluation
Two-sided Student’s t-test from Excel 365 software was used to check for significance
between two measurements. A significant change was adopted for p < 0.05.
3. Results
3.1. Particle Characterization
In a first step, the manufactured nanostructured cylindrical microparticles (microrods)
consisting of 260 nm mesoporous silica nanoparticles (mSNPs) were characterized by
observing the morphology using SEM and CLSM. Therefore, unlabelled nanoparticles were
stained with rhodamine B to generate a fluorescence signal for CLSM imaging on the one
hand and to be able to perform quantification by fluorometry in the NGI experiments
on the other hand. Due to the large number of hydroxy groups on the surface of the
mSNPs and the resulting strongly negative zeta potential of −40.03 ± 0.80 mV (Table 1),
these groups are well suited for chemical modification of the surface [63]. Commonly,
3-aminopropyltrimethoxy silane (APTS) is used as a coupling agent preparing the surface
of silica nanoparticle to be stained with dyes [35]. As demonstrated in Table 1, surface
modification with APTS led to a change in zeta potential to 36.07± 0.57 mV, which turns less
positively charged after coupling rhodamine B to the amino groups (22.70 ± 1.06 mV), but
is still sufficient to be coated during the layer-by-layer procedure. The size of the particles
remains constant due to the modification of the surface, with a small decrease after covalent
binding of rhodamine B. This phenomenon can be explained by the fact that rhodamine
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B reduces the polarity of the particles, which results in reduced water association at the
surface of the particles and therefore a decrease in the hydrodynamic diameter [64].
Table 1. Hydrodynamic diameter, PDI and zeta potential of the unmodified mSNPs, covalently
bound APTS and with rhodamine B and APTS-modified mSNPs. The numbers presented show
that APTS modification leads to a change of zeta potential from negative to positive values without
influencing the hydrodynamic diameter.
Unmodified mSNPs APTS ModifiedmSNPs
Rhodamine B + APTS
Modified mSNPs
Hydr. Diameter (nm) 262.13 ± 3.98 263.23 ± 1.33 245.8 ± 2.97
PDI 0.102 ± 0.013 0.045 ± 0.022 0.084 ± 0.068
Zeta potential (mV) −40.03 ± 0.80 36.07 ± 0.57 22.7 ± 1.06
After staining, the mSNPs were first characterized by microplate spectrophotometer
to check if the functionalization process was successful (Figure S3); afterwards, they were
used as building blocks for the microrods. To characterize the mesoporous structure of the
particles, they were imaged using TEM. Here, the porous structure and the associated large
pore volume were clearly visible (Figure S1). In the beginning, an unloaded batch was
produced to verify the process of staining and subsequent stabilization by the layer-by-layer
technique to the microrods. As illustrated in Figure 1, the formation of such nanostructured
cylinders could be successfully achieved as demonstrated by SEM (Figure 1a,b). The
successful modification with the fluorescent probe is clearly visible by CLSM, showing
the respective cylindrical form of the particles (Figure 1c). Both images depict cylinders
in the expected size range. The template-assisted approach allowed the production of the
microrods with a defined length of 10 µm and width of 3 µm. The microparticles seem to
assemble in larger arrangements and piles, as obvious from the SEM micrographs due to
drying. Looking at redispersed conditions in aqueous environment, it can be clearly seen
that the particles are not agglomerated but well separated from each other. The Neubauer
counting chamber was used to determine the number of particles per membrane, resulting
in 6 × 106 rods per membrane. The length-width ratio (aspect ratio) chosen here is 3.3,
which is assumed to delay uptake of the particles into macrophages compared to spherical
particles [65]. This prolongation of internalization favours longer retention in the lungs
and slower degradation of the active ingredients, thus increasing effectiveness [66].




Figure 1. The microparticle formulation composed of mSNP functionalized with rhodamine B vis-
ualized (a) and (b) by SEM and (c) by CLSM. In all three images, the cylindrical shape can be seen. 
In (a), the particles are not well dispersed due to drying effects. With higher magnification used in 
(b), the nanostructure of the formulation is visible. (c) The formulation was visualised by CLSM 
with λex = 545 nm, λem = 567 nm, dispersed in water. The homogeneous particle dispersion is clearly 
visible, and the fluorescent signal indicates that the functionalization with rhodamine B was suc-
cessful. Representative sections were used for all images. Scale represents 10 µm for (a) and (c) and 
1 µm for (b). The brightness of the CLSM image (c) has been increased for better visibility. 
3.2. Evaluation of Aerodynamic Properties by Next Generation Impactor 
After verifying the morphology of the fluorescently labelled microrods, the flight 
characteristics were determined by NGI. The determination of these parameters is of in-
terest to get an estimation if the formulation may be able to reach the deep lungs. To enable 
deposition in the deep lungs, an aerodynamic diameter of 1–5 µm must be realized [67]. 
For the microrod formulation, an MMAD of 2.85 ± 0.44 µm was determined, which is fa-
vourable for deposition in the deep lungs [68]. The percentage of the mass of particles < 5 
µm, represented by the FPF [69], is with a value of 32.86 ± 2.93% in an acceptable range 
compared to many commercially applied DPIs [70]. This value is mainly promoted by 
coating with L-leucine, which reduces hygroscopicity and increases surface roughness, 
resulting in a powder with less agglomeration and better flow properties [48–50].  
Having a closer look at the MMAD of the microrods, it is evident that the value of 
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equal to one [71], while keeping the other parameters of the equation constant, the value 
under the root decreases, leading to a lower aerodynamic diameter (da) for the same vol-
ume equivalent diameter (dve). This value underlines the advantageous properties of the 
nanostructured cylinders for aerosol application. Looking at the aerodynamic parameters 
with an MMAD of 2.85 ± 0.44 µm and an FPF of >30%, they are found in the relevant range 
for deep lung deposition, thus enabling lung application [67,74,75]. 
Figure 1. The microparticle formulation composed of mSNP functionalized with rhodamine B visualized (a,b) by SEM and
(c) by CLSM. In all three images, the cylindrical shape can be seen. In (a), the particles are not well dispersed due to drying
effects. With higher magnification used in (b), the nanostructure of the formulation is visible. (c) The formulation was
visualised by CLSM with λex = 545 nm, λem = 567 nm, dispersed in water. The homogeneous particle dispersion is clearly
visible, and the fluorescent signal indicates that the functionalization with rhodamine B was successful. Representative
sections wer used for all images. Scale represents 10 µm for (a,c) and 1 µm for (b). The brightness of the CLSM image (c)
has been increased for better visibility.
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3.2. Evaluation of Aerodynamic Properties by Next Generation Impactor
After verifying the morphology of the fluorescently labelled microrods, the flight char-
acteristics were determined by NGI. The determination of these parameters is of interest
to get an estimation if the formulation may be able to reach the deep lungs. To enable
deposition in the deep lungs, an aerodynamic diameter of 1–5 µm must be realized [67].
For the microrod formulation, an MMAD of 2.85 ± 0.44 µm was determined, which is
favourable for deposition in the deep lungs [68]. The percentage of the mass of parti-
cles < 5 µm, represented by the FPF [69], is with a value of 32.86 ± 2.93% in an acceptable
range compared to many commercially applied DPIs [70]. This value is mainly promoted
by coating with L-leucine, which reduces hygroscopicity and increases surface roughness,
resulting in a powder with less agglomeration and better flow properties [48–50].
Having a closer look at the MMAD of the microrods, it is evident that the value of
2.85 µm is lower than both the length and width of the particles. This is in accordance
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Cc(dve) = Cunningham slip correction factor of the volume equivalent diameter;
Cc(da) = Cunningham slip correction factor of the aerodynamic diameter.
The important parameter in this equation for aspherical particles is the dynamic shape
factor χ. Calculating this factor according to Sturm [73] results in a value of 1.47 for an
aspect ratio of 3.3. This means that in comparison to spherical particles, where χ is equal
to one [71], while keeping the other parameters of the equation constant, the value under
the root decreases, leading to a lower aerodynamic diameter (da) for the same volume
equivalent diameter (dve). This value underlines the advantageous properties of the
nanostructured cylinders for aerosol application. Looking at the aerodynamic parameters
with an MMAD of 2.85 ± 0.44 µm and an FPF of >30%, they are found in the relevant range
for deep lung deposition, thus enabling lung application [67,74,75].
3.3. Drug Loading and Release Kinetics
The microrods were loaded with two different drugs exerting anti-inflammatory ef-
fects to generate a combined and enhanced biological effect in comparison to one drug
alone, and thus the inhibition of TNF-α release after inflammation was stronger. Therefore,
curcumin was loaded into the pores of the mSNPs, as they create a protective environ-
ment [18] which leads to a slower degradation of this instable drug [76]. To determine the
highest possible loading of the pores, a BET measurement was performed. A pore volume of
0.1675 ± 0.0089 cm3/g was found, leading to a possible loading of approx. 22% loaded mass
of curcumin with respect to the particles’ weight. To confirm this theoretical maximum load-
ing experimentally, the mSNPs were loaded with 5–20% curcumin and then the pore volume
was determined (Figure S2). The results showed that at 20% loading, only 0.0298 (cm3/g) of
the pore volume remained free, confirming the calculated maximum loading of approx. 22%.
For the preparation, the amounts were chosen in such a way that a load of 20% (m/m) would
be theoretically achievable. To show that only the pores are filled in the loading method
performed, non-porous particles were also attempted to be loaded. No fluorescence signal
was detected here, which excluded a loading of the surface with curcumin.
The siRNA was adsorbed to the surface of the microrods during the stabilization step
using the layer-by-layer technique. In a first step, the loaded formulation was visualized
with both SEM and CLSM, as the curcumin is fluorescent, and the siRNA used was stained
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with ethidium bromide. As shown in Figure 2, curcumin (C) and siRNA against TNF-α (D)
can be visualized fluorometrically. The signal obtained indicates that the entire formulation
is homogeneously loaded with both substances (inserts). When looking at the morphology
under the SEM (Figure 2A,B), the nanostructured cylindrical shape of the microrods can be
seen without affecting the stability.




Figure 2. The curcumin and siRNA loaded formulation under the SEM (A,B) and CLSM (C,D). (A) 
The SEM image shows that neither the stability nor the morphology of the microrods are affected 
by drug loading. (B) Here, the nanostructure as well as the cylindrical shape is visible. (C) Visuali-
zation of curcumin fluorescence of λem = 542 nm was realized after excitation at λex = 440 nm. Here, 
the homogeneous loading of the mSNPs can be seen. (D) To visualize the double-stranded siRNA 
used for CLSM measurement, the formulation was treated with ethidium bromide to generate in-
tercalation, which allowed the detection of a signal at λex = 526 nm, λem = 605 nm. The fluorescence 
is also homogeneously distributed over the whole microparticle surface, as shown in the magnified 
inset of (C,D), indicating a homogeneous loading along the particle. Representative sections were 
used for all images. Scale represents 10 µm for (A,C,D) and 1 µm for (B). 
After successful loading, the release kinetics of the drugs were investigated. There-
fore, an artificial phagolysosomal fluid (PSF) was prepared [58]. This medium was chosen 
for the in vitro release as the microrods are phagocytosed by macrophages due to their 
size [77] after reaching the lungs. Looking at the release kinetics in Figure 3, the siRNA 
shows a sustained release whereas the curcumin exhibits a delayed release. These release 
profiles correspond to the expected results, as the siRNA is directly available due to its 
localization on the surface of the microrods and thus offers a large area to be detached, 
whereas the curcumin is protected twice from release, once by the hydrophobic environ-
ment in the pores and secondly by the polymer layers covering the mSNPs. Consequently, 
the amount of curcumin released was below the detection limit during the first 24 h and 
after 48 h at 15 µg/mg microrods, which is about 8% of the total dose. For siRNA, approx. 
540 ng/mg microrods were released, which is about 15% of the total amount. Thus, after 
48 h, the siRNA was released roughly twice as fast as curcumin. The release profile of 
siRNA, which is characterized by a step pattern consisting of a sharp increase in release 
Figure 2. The curcumin and siRNA loaded formulation under the SEM (A,B) and CLSM (C,D). (A) The SEM image shows
that neither the stability nor the morphology of the microrods are affected by drug loading. (B) Here, the nanostructure
as well as the cylindrical shape is visible. (C) Visualization of curcumin fluorescence of λem = 542 nm was realized after
excitation at λex = 440 nm. Here, the homogeneous loading of the mSNPs can be seen. (D) To visualize the double-stranded
siRNA used for CLSM measurement, the formulation was treated with ethidium bromide to generate intercalation, which
allowed the detection of a signal at λ x = 526 nm, λem = 605 nm. The fluorescence is also ho ogeneo sly distributed over
the whole m croparticle surface, as shown in the magnified inset of (C,D), indic ting a mogeneous loading along the
particle. Repres ntative sections were used for all images. Scale represents 10 µm for (A,C,D) and 1 µm for (B).
After successful loading, the release kinetics of the drugs were investigated. Therefore,
an artificial phagolysosomal fluid (PSF) was p epared [58]. This medium was chosen for the
n vitro re ease as the m crorods are phagocytosed by macrophages due to th ir size [77] after
reaching the lungs. Looking t the release kinetics in Figure 3, the siRNA shows a sustained
release wher as the curcumin exhibits a delayed release. These release profiles correspond to
th expected results, as the siRNA s directly available u to its localization on the surface of
the micr rods and thus offers a l rge area to be detached, whereas the curcumin is protected
twic from r lease, once by the hydrophobic nvironm nt in the pores nd secondly by the
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polymer layers covering the mSNPs. Consequently, the amount of curcumin released was
below the detection limit during the first 24 h and after 48 h at 15 µg/mg microrods, which is
about 8% of the total dose. For siRNA, approx. 540 ng/mg microrods were released, which
is about 15% of the total amount. Thus, after 48 h, the siRNA was released roughly twice
as fast as curcumin. The release profile of siRNA, which is characterized by a step pattern
consisting of a sharp increase in release leading to a plateau followed by a slower increase, is
favoured by several factors. These are, on the one hand, the swelling of the polymer layers,
as well as an ion exchange with the surrounding counterions and the detachment of the
various layers. This influences the release of the different polymers and thus also of the
siRNA, which results in the release pattern observed [78,79].
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Figure 3. In vitro release kinetics of siRNA (a) and curcumin (b) in PSF for 48 h at 37 ◦C under gentle shaking. The release
profiles show that the two drugs were released with different kinetics. The curcumin, which was located in the pores of the
mSNPs and covered by various polymers, was only detected after 24 h. After two days, 15 µg per mg rods were released,
whic is about 8% of the total load. The siRNA found on the surface of the microrods was released continuously with a final
amount of about 540 g per mg mic oro s after 48 h, which i bout 15% of the load. For each time point, three individual
experiments were performed and the mean values as well as standard deviation were determined (n = 3).
3.4. Cell Viability of Alveolar Basal Epithelial Cells and Macrophages
After the particles were successfully loaded with the selected anti-inflammatory drugs,
acute cytotoxicity w evaluated. Since during p lmonary a plication immunol g ally
active cells as well as epithelial cells encounter the applied formulat on, a toxicity test was
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performed on both A549 cells as model for alveolar epithelial cells as well as on dTHP-1
cells as a macrophage cell line. As illustrated in Figure 4, the MTT assay showed no toxicity
for 10 to 100 µg/mL up to an incubation time of 48 h. Here, the loaded microrods represent
20% curcumin loading and siRNA against TNF-α in the outermost layer and the unloaded
microrods are the formulation without any drug. The concentrations used per cell were
chosen to provide the same conditions as in the ELISA performed subsequently. Since no
toxicity was generated by the selected parameters, the formulation was used to determine
the effect on the cytokine release.
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Figure 4. Determination of cell viability after incubation of the human alveolar epithelial cell line A549 (upper graph)
and the differentiated human macrophage cell line dTHP-1 (lower graph) with unloaded and curcumin + siRNA loaded
microrods. Incubation times of 4 to 48 h were chosen with a concentration of 10, 50 and 100 µg/mL. These parameters were
adjusted to those of the ELISA performed later to see if the conditions are suitable for cytokine determination, as toxicity
would cause high cytokine levels. Up to 48 h incubation time, no relevant toxicity can be observed.
3.5. TNF-α Quantification via ELISA
The successfully prepared nanostructured microrods loaded with curcumin and
siRNA showing no toxicity on relevant time scales allowed the investigation of the cytokine
inhibition potential of the microrods. The dTHP-1 cells were grown in 24-well plates with
2 × 105 cells per well and incubated with 500 µL of 400 to 40 µg/mL microrods suspension
for 48 h to generate the same rod-to-cell ratio as in the previous MTT assay (no toxicity ob-
served). Subsequently, the cells were incubated for 6 h with LPS to induce an inflammation
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and afterwards cytokine release was measured. In addition to the formulation loaded with
curcumin and siRNA, further control groups were tested for TNF-α inhibition allowing
to separate the effect of the different compounds. Therefore, microrods only loaded with
curcumin as well as curcumin solution were tested. To exclude unspecific gene silencing
by an oligonucleotide sequence, a scrambled siRNA with the same number of base pairs
was used as control. Additionally, all drugs were used without a carrier system to check
their behaviour with respect to cytokine inhibition. As positive control (PC), dTHP-1 were
cultivated without LPS stimulation whereas for the negative control (NC), cells were only
incubated with LPS for 6 h without any drug delivery system or drug applied. Comparing
the results of the ELISA (Figure 5), the microrods loaded with both anti-inflammatory
reagents were found to be most powerful and inhibit the TNF-α release significantly in
comparison to the NC, as well as the loaded formulation with just one drug. In addition,
the unspecific siRNA and the pure drugs without a carrier system had no influence on
cytokine inhibition, as expected. This demonstrates that loading the microrods with two
drugs has a positive effect on TNF-α reduction. Furthermore, this approach is significantly
more effective than applying just one drug. Additionally, the results obtained show that
the developed nanostructured cylindrical microparticles loaded with curcumin and siRNA
is a drug delivery system with suitable properties to reduce inflammation reactions of
macrophages in the lungs. The release kinetics only providing a small fraction of the loaded
drug released after two days might be also a beneficial aspect for future in vivo studies, as
the reduction in the inflammation will not only last 48 h.
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Figure 5. Determination of TNF-α release after incubation with different formulations for 48 h followed by LPS stimulation.
As NC, cells were stimulated only with LPS without any carrier system, whereas the PC represents unstimulated cells.
In order to compare the microrods loaded with both active ingredients (Rods Cur+siRNA) and the individually loaded
microrods, a formulation containing only curcumin (Rods Cur) and only siRNA (Rods siRNA) were prepared and its
influence on cytokine releas determined. T exclude possible unspecific gene silencing by an oligonucleotide sequence,
scrambled siRNA ith the same numb r of base pairs was used as an additional control. I addition, the drugs were
applied to the cells with ut a carrier system to show the influence of the microrods as a m ans of transport. The results
obtained show that the formulation with both active ingredients can significantly reduce the TNF-α release in contrast to the
formulations with just one drug, or the active ingredients without carrier. Moreover, no unspecific inhibition by scrambled
siRNA was observed. However, it can also be seen that all microrod formulations can inhibit cytokine release, which shows
that the cylindrical microparticles can effectively transport the active ingredients into the macrophages. Significance of the
obtained data was calculated by two-sided Student’s t-test. * p < 0.05.
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4. Discussion
This manuscript described the stepwise production of a nanostructured cylindrical
microparticle system for pulmonary application, loading two anti-inflammatory drugs to
reduce TNF-α release by human macrophage cell line THP-1. Mesoporous silica nanopar-
ticles were used as building blocks of these microparticles as they have various positive
properties in terms of drug delivery. Due to their large specific surface area and pore
volume, high quantities of drugs can be loaded into the pores and additionally this porous
structure leads to an improved biocompatibility [80]. Another advantage of pore loading
is the protection of unstable drugs such as curcumin due to the protective environment
created in the pores [18]. This property was taken advantage of when loading curcumin, as
this anti-inflammatory drug [81] is subject to rapid degradation [29] and thus should be
transported as closely as possible to the target. After loading the mSNPs, they had to be
moved to a next larger dimension, since the aerodynamic properties were not sufficient to
reach the deep lungs [67]. To allow for formation of inhalable objects, the layer-by-layer
technique was used to increase the adhesion forces of the nanoparticles to each other
and thus the integrity of the cylinders. Thus, a stable microparticulate formulation was
generated. Various polyionic polymers can be used in this technique, but also biomolecules
such as proteins, polypeptides and nucleic acids [82]. The aerodynamic properties of
such a hierarchical system loaded with two types of anti-inflammatory drugs should offer
a potential for lung deposition with values below the diameter of the template and the
microcylinders (<3 µm). In the developed formulation, a specific siRNA against TNF-α
was used as layering material to stabilize the formulation and to act at the same time as
anti-inflammatory active ingredient. The delivery of siRNA faces many hurdles due to the
chemical structure. The typically low stability, as well as the membrane impermeability
caused by the polyanionic character are the biggest challenges [83]. As the target location
of siRNA is the cytoplasm [84], branched polyethyleneimine was used as polycationic
polymer for stabilisation, as this molecule has a strong buffering capacity, which promotes
osmotic swelling of the lysosome and thus destabilizes the membrane of the vesicle, leading
to diffusion of the siRNA in the cytoplasm (proton sponge effect) [43]. A provision of siRNA
and curcumin without the delivery system did not impact the TNF-a secretion. However,
the combination of both anti-inflammatory drugs with the developed drug delivery system
showed a significant reduction in cytokine release compared to the individual agents. This
suggests that the combination of two such drugs will allow stronger effects in reducing the
inflammatory status.
The use of different particle shapes for drug delivery has been of increasing inter-
est in recent years [85]. For lung application, a cylindrical shape is of interest, since on
the one hand the aerodynamic properties are suitable for inhalation (as described in the
manuscript), and on the other hand the particle–cell interaction is different to spherical
particles. By changing the aspect ratio of the microrods, particle uptake into macrophages
can be prolonged [33], which allows a sustained residence time of the formulation and
the active ingredient. A sustained release was also previously demonstrated in vivo for
cylindrical microparticles using plasmid DNA, where a biological output was detected after
five days [25]. In addition, the surface of the cylindrical nanostructured microparticles is
significantly higher than their spherical counterparts due to the large internal surface. This
allows a larger amount of drugs to be loaded. Thus, larger quantities can be transported to
the target cell population, which is particularly important for siRNA delivery [86]. Espe-
cially, the effective transport of siRNA into the lungs is still a major hurdle at present [87].
However, the data discussed above in terms of pulmonary deposition (NGI data) and the
inhibition of TNF-a release (ELISA data) depict an intriguing direction with respect to
co-application as well as with respect to novel formulation approaches.
5. Conclusions
The delivery of curcumin and siRNA is difficult due to chemical properties of the two
compounds. Therefore, it is important to develop suitable drug carrier systems to enable
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effective transport. Due to the rapid decay of curcumin, protection of this substance is
particularly important. This was provided by the pores of the mSNPs and the protective
environment formed there, as well as the polymer layers above. The loading, as well
as the transport of siRNA to macrophages, could be successfully evaluated, resulting
in a significant reduction in TNF-α release. The combination of both anti-inflammatory
drugs proved to be the most efficient. Besides the positive biological results, the obtained
aerodynamic characteristics with a MMAD of 2.85 µm and a FPF > 30% render a possible
pulmonary application feasible using such systems.
In summary, the developed nanostructured cylindrical particle formulation is suitable
for the transport of labile drugs and, due to its flight properties, can enable transport into
the lungs. In addition, the formulation is non-toxic to both alveolar epithelial cells and
macrophages and can significantly inhibit TNF-α release after inflammation with LPS,
making it a potential alternative to a drug delivery system for the lungs.
This approach can be used to deliver macromolecular and small drugs to efficiently
treat pulmonary diseases. The specific interaction due to their size with macrophages in
combination with the straightforward loading approach by adsorbing the macromolecular
drug promise to be an interesting carrier system also for other diseases where macrophages
play central roles in inflammation (e.g., COVID-19) or even bacterial infections such as
tuberculosis. The variability of loading should allow a broad field of application; for this,
the release must be controlled and further developed and the production must be further
industrialized. With these issues addressed, the potential modulation of the biological
effects, uptake time und connected residence time are promising targets.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13060844/s1, Figure S1: TEM images of the mSNP, visualizing the mesoporous
structure. Both magnifications (a) 20 kX and (b) 50 kX illustrate the sponge-like structure, which
indicates a large pore volume to load high amounts of drug. Figure S2: Correlation between total
pore volume and loading amount of curcumin. The experimental determination of the maximum
loading amount shows that at a loading of 20% almost all pores are filled. This also corresponds to
the calculated maximum pore loading of approx. 22%. For each loading amount, two individual
measurements were performed (n = 2). Figure S3: Calibration curve of mSNPs functionalized
with rhodamine B at λex = 545 nm, λem = 570 nm. For each measuring point, three individual
measurements were performed (n = 3).
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